Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.…
NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
Vanda Pharmaceuticals (NASDAQ: VNDA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 533 employees.
The shares were at 3.445 USD on 20 November 2026, down 21.9% over 52 weeks. Its 52-week range is 3.415 USD to 9.940 USD, and it trades at the bottom of that range.
Its market capitalisation is 208.32M USD.
Vanda Pharmaceuticals reports return on equity of -67.4%, an operating margin of -77.6% and revenue up 24.1% year over year.
It holds more cash than debt, a net cash position of 118.52M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock; their mean price target of 11.50 USD is 233.8% above the current price. The next earnings report is expected on 17 February 2027.